Cargando…

Senescence-associated reprogramming induced by interleukin-1 impairs response to EGFR neutralization

BACKGROUND: EGFR targeting is currently the main treatment strategy for metastatic colorectal cancer (mCRC). Results of different clinical trials show that patients with wild-type KRAS and BRAF benefit from anti-EGFR monoclonal antibodies (moAbs) cetuximab (CTX) or panitumumab. Unfortunately, despit...

Descripción completa

Detalles Bibliográficos
Autores principales: Romaniello, Donatella, Gelfo, Valerio, Pagano, Federica, Ferlizza, Enea, Sgarzi, Michela, Mazzeschi, Martina, Morselli, Alessandra, Miano, Carmen, D’Uva, Gabriele, Lauriola, Mattia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903543/
https://www.ncbi.nlm.nih.gov/pubmed/35236282
http://dx.doi.org/10.1186/s11658-022-00319-7

Ejemplares similares